{"id":2008,"date":"2017-03-28T12:03:45","date_gmt":"2017-03-28T12:03:45","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2008"},"modified":"2021-07-24T12:56:42","modified_gmt":"2021-07-24T07:26:42","slug":"notizia-32","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-32","title":{"rendered":"Tesaro puts AstraZeneca; XELJANZ\u00ae receives; Innovus nabs; Alexion brings"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a05b6d23a5c9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a05b6d23a5c9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-32\/#Tesaro_puts_AstraZeneca_on_notice_with_early_FDA_nod_for_Lynparza_rival_niraparib\" >Tesaro puts AstraZeneca on notice with early FDA nod for Lynparza rival niraparib<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-32\/#XELJANZ%C2%AE_receives_marketing_authorisation_in_the_EU_for_moderate_to_severe_rheumatoid_arthritis\" >XELJANZ\u00ae receives marketing authorisation in the EU for moderate to severe rheumatoid arthritis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-32\/#Innovus_Pharma_nabs_European_patent_for_Sensum\" >Innovus Pharma nabs European patent for Sensum+<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-32\/#Alexion_brings_on_former_Baxalta_chief_Hantson_to_fill_vacant_CEO_spot\" >Alexion brings on former Baxalta chief Hantson to fill vacant CEO spot<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Tesaro_puts_AstraZeneca_on_notice_with_early_FDA_nod_for_Lynparza_rival_niraparib\"><\/span>Tesaro puts AstraZeneca on notice with early FDA nod for Lynparza rival niraparib<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Tesaro\u2019s closely watched ovarian cancer drug niraparib\u2014now dubbed Zejula\u2014won an FDA nod on 27<sup>th<\/sup> March, months before its scheduled decision date. Apart from getting approval, Zejula also got a broader label than its head-to-head rival, Lynparza from AstraZeneca. It\u2019s approved to treat all women with recurrent ovarian, fallopian tube or peritoneal cancer who\u2019ve previously responded to platinum chemo, not just those who test positive for the BRCA genetic mutation. With 2022 sales expectations of $1.9 billion, Zejula is one of the top drug launches of 2017. And with some strong data showing its ability to hold off cancer progression for more than a year in some patients, it could be a quick challenger for market share when it launches, expected in late April.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"XELJANZ%C2%AE_receives_marketing_authorisation_in_the_EU_for_moderate_to_severe_rheumatoid_arthritis\"><\/span>XELJANZ\u00ae receives marketing authorisation in the EU for moderate to severe rheumatoid arthritis<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Pfizer Inc. announced that the European Commission (EC) has approved XELJANZ\u00ae 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). XELJANZ can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. XELJANZ belongs to a new class of therapies called Janus kinase (JAK) inhibitors. The EC approval is based on a submission package that included results from the Phase 3 Oral Rheumatoid Arthritis triaLs (ORAL) global development program and real world data.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Innovus_Pharma_nabs_European_patent_for_Sensum\"><\/span>Innovus Pharma nabs European patent for Sensum+<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Innovus Pharmaceuticals received a Notice of Intention to Grant from the European Patent Office for a patent titled &#8220;Sensitization composition and method of use&#8221; covering its Sensum + product for reduced penile sensitivity. The Notice of Intention to Grant from the EPO adds great value to the CPNP notification to market Sensum+\u00ae in Europe. Having a patented product has increased the ability of the company to enter into new commercial partnerships for Sensum+\u00ae in Europe. Sensum + is a non-medicated cream used by men to enhance sexual satisfaction.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Alexion_brings_on_former_Baxalta_chief_Hantson_to_fill_vacant_CEO_spot\"><\/span>Alexion brings on former Baxalta chief Hantson to fill vacant CEO spot<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Alexion\u2019s CEO search is over. The Connecticut biotech, which bade its skipper farewell late last year, is bringing former Baxalta chief Ludwig Hantson into the fold. Hantson will take the reins from David Brennan, who stepped in as interim CEO after David Hallal made his exit last December. Brennan will remain on Alexion\u2019s board, which expects to appoint him chairman at the company\u2019s mid-May annual meeting, Alexion said.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tesaro puts AstraZeneca on notice with early FDA nod for Lynparza rival niraparib Tesaro\u2019s closely watched ovarian cancer drug niraparib\u2014now dubbed Zejula\u2014won an FDA nod on 27th March, months before its scheduled decision date. Apart from getting approval, Zejula also got a broader label than its head-to-head rival, Lynparza from AstraZeneca. It\u2019s approved to treat [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1965,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[885,96,17498,705,709,704,17497,1303,2117,730,17496,712,639,2019],"industry":[17225],"therapeutic_areas":[17227,17228,17411],"class_list":["post-2008","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alexion","tag-astrazeneca","tag-baxalta","tag-drug-approval","tag-ema","tag-fda","tag-innovus-pharma","tag-lynparza","tag-niraparib","tag-notizia","tag-peritoneal-cancer","tag-pharma-industry","tag-pharma-news","tag-rheumatoid-arthritis","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tesaro puts AstraZeneca; XELJANZ\u00ae receives; Innovus nabs<\/title>\n<meta name=\"description\" content=\"Tesaro\u2019s closely watched ovarian cancer drug niraparib\u2014now dubbed Zejula\u2014won an FDA nod on 27th March, months before its scheduled decision date. Apart...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-32\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tesaro puts AstraZeneca; XELJANZ\u00ae receives; Innovus nabs\" \/>\n<meta property=\"og:description\" content=\"Tesaro\u2019s closely watched ovarian cancer drug niraparib\u2014now dubbed Zejula\u2014won an FDA nod on 27th March, months before its scheduled decision date. Apart...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-32\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-28T12:03:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"520\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tesaro puts AstraZeneca; XELJANZ\u00ae receives; Innovus nabs","description":"Tesaro\u2019s closely watched ovarian cancer drug niraparib\u2014now dubbed Zejula\u2014won an FDA nod on 27th March, months before its scheduled decision date. Apart...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-32","og_locale":"en_US","og_type":"article","og_title":"Tesaro puts AstraZeneca; XELJANZ\u00ae receives; Innovus nabs","og_description":"Tesaro\u2019s closely watched ovarian cancer drug niraparib\u2014now dubbed Zejula\u2014won an FDA nod on 27th March, months before its scheduled decision date. Apart...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-32","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-03-28T12:03:45+00:00","article_modified_time":"2021-07-24T07:26:42+00:00","og_image":[{"width":960,"height":520,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-32","url":"https:\/\/www.delveinsight.com\/blog\/notizia-32","name":"Tesaro puts AstraZeneca; XELJANZ\u00ae receives; Innovus nabs","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-32#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-32#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg","datePublished":"2017-03-28T12:03:45+00:00","dateModified":"2021-07-24T07:26:42+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Tesaro\u2019s closely watched ovarian cancer drug niraparib\u2014now dubbed Zejula\u2014won an FDA nod on 27th March, months before its scheduled decision date. Apart...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-32"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-32#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg","width":960,"height":520},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news-300x163.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alexion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Baxalta<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Drug Approval<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EMA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Innovus Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lynparza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Niraparib<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peritoneal Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rheumatoid arthritis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alexion<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Baxalta<\/span>","<span class=\"advgb-post-tax-term\">Drug Approval<\/span>","<span class=\"advgb-post-tax-term\">EMA<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Innovus Pharma<\/span>","<span class=\"advgb-post-tax-term\">Lynparza<\/span>","<span class=\"advgb-post-tax-term\">Niraparib<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">Peritoneal Cancer<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">rheumatoid arthritis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 28, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 28, 2017 12:03 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2008"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2008\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1965"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2008"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2008"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}